QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders. Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma’s product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales. The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.
QRxPharma’s lead compound, MoxDuo® IR (Q8003IR), is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. Study results consistently demonstrate MoxDuo IR’s greater overall tolerability, achieving as good or better pain relief with substantially fewer incidences of moderate to severe side effects. The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics.
News
US Commercialisation Partner Actavis to be acquired by Watson ![]()
26 April 2012
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR ![]()
11 April 2012
QRxPharma Signs License and Option Agreement with Actavis ![]()
19 March 2012
Webcast Link: QRxPharma Presentation the 32nd Cowen Health Care Conference
5 March commencing at 4:30 pm EST USA (Sydney, Australia: 8.30 am Tuesday, 6 March) ![]()
QRxPharma to Present at the 32nd Cowen Health Care Conference ![]()
2 March 2012
Dr. Edward Rudnic Joins QRxPharma as Chief Operating Officer ![]()
14 February 2012
QRxPharma Announces Strategic Partnership with Actavis ![]()
21 December 2011
QRxPharma Granted Target Date for FDA Action on MoxDuo® IR NDA ![]()
8 November 2011
QRxPharma Completes NDA Submission for MoxDuo® IR ![]()
25 August 2011
Initiation of NDA Filing Caps Off Another Successful Year for MoxDuo® Pain Therapy Development ![]()
18 August 2011
QRxPharma CEO discusses Recent Milestones and Rights Issue
on Boardroom Radio ![]()
[Click here to listen to the broadcast]
10 August 2011
QRxPharma Announces NDA Filing for MoxDuo® IR ![]()
18 July 2011
Additional Data on MoxDuo IR Comparative Safety Study ![]()
29 June 2011
QRxPharma CEO discusses Comparative Safety Study on Boardroom Radio ![]()
15 June 2011
QRxPharma Completes Comparative Safety Study ![]()
14 June 2011
QRxPharma Completes Patient Enrolment of MoxDuo®IR Phase 3 Comparative Safety Study ![]()
27 April 2011
USPTO Issues QRxPharma a New Patent for MoxDuo IR ![]()
14 April 2011
QRxPharma on Track to File New Drug Application Mid-Year ![]()
28 March 2011
FDA Grants QRxPharma Pre-New Drug Application Meeting in March 2011 ![]()
21 February 2011
QRxPharma Initiates Phase 3 Comparative Safety Study of MoxDuo®IR ![]()
24 January 2011
QRxPharma Completes Patient Enrolment of Pivotal MoxDuo® IR Phase 3 Study ![]()
6 December 2010
QRxPharma Completes A$19.8 Million Capital Raising ![]()
19 October 2010
QRxPharma Awarded Additional US$244,479 Grant for TorsinA Program ![]()
8 October 2010
QRxPharma Awarded Grants Totalling US$489,000 for Two MoxDuo® Pain Management Product Candidates ![]()
4 October 2010
QRxPharma Limited Announces A$14 Million Placement together with a Share Purchase Plan ![]()
1 October 2010
QRxPharma to Sponsor Symposium at International Association for the Study of Pain Meeting ![]()
31 August 2010
Frost & Sullivan Recognises QRxPharma's MoxDuo® IR for Innovation in Pain Therapy ![]()
18 August 2010 [Click here to read the Frost & Sullivan Release]
QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for MoxDuo® IV Pain Therapy ![]()
9 August 2010
Webcast Link: QRxPharma Presentation at Noble Financial's Equity Conference
11AM EDT, 7 June 2010 ![]()
1 June 2010
ASX Spotlight: John Holaday, Managing Director and CEO, QRxPharma ![]()
24 May 2010
QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo® IR in Patients with Post-Surgical Pain ![]()
14 April 2010
QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo®IV ![]()
23 February 2010
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo™ IR Dual-Opioid™ for NDA Submission ![]()
10 February 2010
BioTech Nation Podcast with Dr. Moira Gunn [mp3 Audio]
19 January 2010
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo™IR For Moderate to Severe Acute Pain ![]()
30 November 2009
QRxPharma Limited Announces A $21.6 Million Fully Underwritten Capital Raising ![]()
16 November 2009
QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets 
20 October 2009
QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo™CR ![]()
12 October 2009
MoxDuo™ IR Demonstrates Fewer Side Effects than Percocet® ![]()
26 August 2009
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo™ IV Pain Therapy ![]()
23 July 2009
QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy ![]()
20 April 2009
QRxPharma Initiates Second Comparative Study for MoxDuo™ IR Dual-Opioid™ Pain Therapy ![]()
19 February 2009
QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy ![]()
16 December 2008
QRxPharma and University of Alabama at Birmingham Collaborate on Research Program for Parkinson’s Disease ![]()
29 October 2008
FDA Accepts Streamlined Phase 3 Development Plan for Q8003IR “Dual Opioid” Pain Therapy ![]()
5 August 2008
QRxPharma Begins Trading on the International OTCQX ![]()
1 July 2008
QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy ![]()
22 May 2008
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy ![]()
5 May 2008
Bioshares: The Commercial Context for QRxPharma’s QR8003 ![]()
11 April 2008
The Commercial Context for QRxPharma’s QR8003QRxPharma Limited Interim Report for the half-year ended 31 December 2007 ![]()
26 February 2008
QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy ![]()
13 December 2007
QRxPharma Moving Rapidly with First Patients Enrolled in Phase III Clinical Trial Programme for its “Dual Opioid” Pain Therapy ![]()
The Australian Investor, November 2007
QRxPharma Doses First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy ![]()
26 November 2007
QRxPharma Annual report 2007 ![]()
27 September 2007
JP Morgan Analyst Report ![]()
4 July 2007
QRxPharma Trials Recipe for Pain Relief ![]()
28 June 2007 - The Australian Financial Review
Australian firm combines with local biotech entrepreneur in U.S. venture
21 June 2007 - Washington Business Journal
QRxPharma Completes $50 Million IPO; Trading Commences on the Australian Securities Exchange ![]()
25 May 2007